

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
(Stock code: 8189)

## **APPOINTMENT AND REDESIGNATION OF JONIT CHIEF EXECUTIVE OFFICER**

The Board (the “**Board**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) hereby announces that Ms. Lynn Li has been appointed as the Joint Chief Executive Officer of the Company and Ms. Sun Li has been re-designated as the Joint Chief Executive Officer of the Company from the Chief Executive Officer of the Company with effect from 31 March 2026.

### **Ms. Lynn Li**

Ms. Lynn Li (“**Ms. Lynn**”), aged 41, is a seasoned business leader and strategic expert deeply rooted in the frontier intersection of Biotechnology and Artificial Intelligence (AI). She holds a Ph.D. in Chemistry from the University of Vienna and a Master of Science in Management from Stanford Graduate School of Business. Ms. Lynn has a distinguished track record of transforming cutting-edge medical technologies into successful commercial outcomes. She previously served in strategic research and cross-disciplinary project management roles at prestigious academic institutions, where she spearheaded high-value research initiatives and holds 163 patents and licenses globally. As a veteran tech entrepreneur, Ms. Lynn has demonstrated exceptional insight into capital markets, having led enterprises to secure over US\$100 million in funding across multiple rounds.

Ms. Lynn excels in data-driven operational excellence, achieving exponential business growth, including a ten-fold increase in revenue within four years. Her commercial achievements and leadership have been widely recognized, earning her accolades such as “20 Women to Watch in Business” by Forbes China and “40 Under 40” by Fortune China.

Ms. Lynn will assume overall responsibility for the technical iteration, business expansion, and capital markets strategy of the Group’s “AI Medical Large Model MaaS Platform”, including specifically the following:

- Drive technological iteration and upgrades to the MaaS platform: Leveraging expertise in AI algorithm integration and medical data modeling, Ms. Lynn will lead the ongoing optimization of the Group’s MaaS platform, drive iterative upgrades to the “Xihe No. 1” medical large model and the full-stack AI technology, and reduce deployment costs through standardized service processes.
- Accelerate the market rollout of the MaaS platform: Leveraging her extensive commercial operations experience, Ms. Lynn will lead the deepened deployment of the Group’s MaaS platform in flagship projects in Xiamen, Yinchuan, etc., continue to refine the dual-revenue model comprising platform development fees and token usage fees, and explore the application and monetization of AI model services across diverse scenarios, including primary healthcare facilities and medical data services.
- Strategic operation and conversion of technology assets: Leveraging her extensive experience in patent management and the conversion of academic research into commercial applications, Ms. Lynn will be responsible for optimising the Group’s technology asset portfolio and accelerating the transformation of laboratory outputs into high-margin commercial products.
- Capital operations and international layout: Building on her distinguished fundraising background and international perspective, Ms. Lynn will be responsible for the Group’s strategic partnerships, capital allocation and the development of a composite technology talent pipeline on a global basis, thereby enhancing the Company’s valuation potential and brand influence in the international digital healthcare market.

The Board believes that Ms. Lynn’s keen commercial insight and deep cross-disciplinary “Health+AI” background will significantly accelerate the commercialization of the Group’s MaaS platform, and her exceptional capital management capabilities will further enhance the Company’s valuation potential and brand influence in international markets, driving the Group towards a new phase of transformative growth.

Following the appointment of Ms. Lynn as the Joint Chief Executive Officer of the Company, her service agreement with the Company has commenced on 31 March 2026 and will expire on 31 March 2027. Subsequently, the agreement will be renewed after submission to the Board for approval. Ms. Lynn is entitled to an annual emolument of RMB1,500,000, comprising a basic salary and a performance bonus, with the performance bonus determined by reference to the Company's annual performance targets and the results of individual performance assessments. The remuneration of Ms. Lynn is determined by reference to her duties and responsibilities in the Company and the prevailing market conditions.

### **Ms. Sun Li**

Ms. Sun Li (“**Ms. Sun**”), aged 53, the Chairman of the Board of the Company. Graduated from the Economic and Trade Faculty of Central South University with a bachelor's degree in Technological Economics in June 1995 and with a master's degree in Management Business Administration Faculty in June 1998, she also graduated from City University of Hong Kong with a PhD in Business Administration in 2021. Ms. Sun was among the first batch of candidates who obtained the qualification of sponsor representatives from the Securities Association of China in 2004. Ms. Sun has engaged in investment banking for 15 years, with rich experience in filtering quality corporations, restructuring, counselling, initial public offering projects as well as mergers and acquisitions of listed companies. From August 1998 to April 2004, she successively acted as business director, senior manager, and business manager at the investment banking headquarter of Dapeng Securities Co., Ltd. (大鵬證券有限責任公司). From May 2004 to August 2005, she served as deputy general manager in Shenzhen investment banking division of Centergate Securities Co., Ltd. (中關村證券股份有限公司). From September 2005 to March 2010, she successively served as business director, internal audit committee member, member of GEM's advisory committee at the investment banking headquarter of China Merchants Securities Co., Ltd. (招商證券股份有限公司). From April 2010 to April 2013, she served as general manager and internal audit committee member in mergers and acquisitions division of Minsheng Securities Co., Ltd. (民生證券有限責任公司). From May 2013 until now, she served as president, director and co-partner of Beijing Yingguxinye Investment Co., Ltd (北京盈谷信曄投資有限公司). From September 2014 until now, she was the founding member of Tianjin Teda “Wings of the Angel” Investor Club. From August 2015 until now, Ms. Sun was appointed as an executive director and the chairman of the Board of the Company. From September 2015 to January 2019, from December 2019 to September 2022 and since March 2024, she has also served as chief executive officer of the Company. From September 2022 to March 2024, she also served as the Joint Chief Executive Officer of the Company.

Ms. Sun has entered into a letter of appointment as an executive director with the Company for a term of three years commencing from 31 December 2025. Ms. Sun will be entitled to a remuneration of RMB530,000 per annum. Ms. Sun's remuneration is determined with reference to her responsibilities and duties in the Company and the prevailing market condition.

As at the date of this announcement, Ms. Sun serves as the chairman of the Board, an executive director, the chairman of the nomination committee, a member of the remuneration committee of the Company and a director and general manager of several subsidiaries of the Group.

As at the date of this announcement, neither Ms. Sun nor Ms. Lynn holds any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Ms. Sun and Ms. Lynn (i) do not hold any other position with the Company or other members of the Company; (ii) do not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) do not hold any directorship in public companies for the last three years, the securities of which are listed in Hong Kong or any other overseas securities markets, and do not have any other major appointments or professional qualifications. Each of Ms. Sun and Ms. Lynn confirms that, save as disclosed above, there is no information relating to the appointment and re-designation of Joint Chief Executive Officer that is required to be disclosed pursuant to Rules 17.50(2)(h) to (v) of the GEM Listing Rules of the Stock Exchange, and there are no any other matters that need to be brought to the attention of the shareholders of the Company.

The Board extends its congratulations to Ms. Lynn on her appointment as Joint Chief Executive Officer of the Company and to Ms. Sun on her re-designation as Joint Chief Executive Officer.

By order of the Board

**Tianjin TEDA Biomedical Engineering Company Limited**

**Sun Li**

*Chairman*

Tianjin, the PRC

31 March 2026

*As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. Yang Zeng and Mr. Xia Alan Zhe, respectively; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing and Mr. Wang Lei, respectively; the independent non-executive directors of the Company are Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang, respectively.*

*This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no any other matters the omission of which would make any statement herein or this announcement misleading.*

*This notice will remain on the GEM website at <http://www.hkgem.com> on the “Latest Listed Company Information” page for seven(7) days from the date of its posting, and it will also be published and remained on the website of the Company at [www.bioteda.com](http://www.bioteda.com).*